Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Cash from Investing Activities (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Cash from Investing Activities for 16 consecutive years, with -$40598.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Investing Activities fell 540.33% year-over-year to -$40598.0, compared with a TTM value of -$404336.0 through Sep 2025, down 594.01%, and an annual FY2024 reading of -$291718.0, down 2432.93% over the prior year.
  • Cash from Investing Activities was -$40598.0 for Q3 2025 at China Pharma Holdings, down from -$9921.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $55964.0 in Q1 2023 and bottomed at -$415977.0 in Q3 2021.
  • Average Cash from Investing Activities over 5 years is -$82108.7, with a median of -$9921.0 recorded in 2025.
  • The sharpest move saw Cash from Investing Activities skyrocketed 4123.29% in 2023, then plummeted 5927.21% in 2024.
  • Year by year, Cash from Investing Activities stood at -$7056.0 in 2021, then skyrocketed by 486.45% to $27268.0 in 2022, then plummeted by 116.6% to -$4527.0 in 2023, then tumbled by 5927.21% to -$272852.0 in 2024, then surged by 85.12% to -$40598.0 in 2025.
  • Business Quant data shows Cash from Investing Activities for CPHI at -$40598.0 in Q3 2025, -$9921.0 in Q2 2025, and -$80965.0 in Q1 2025.